Multifarious Pharmacotherapeutic Perspectives of Some Natural Bromophenol Compounds: In silico Enzyme Inhibitory Potentials
Keywords:
Bromophenol, Molecular docking, In silico, Therapeutic target, Multi-targeted, InhibitorsAbstract
The process of drug discovery, design, and development often designated as 3Ds has played enormous role in modern era. The present research investigation includes in silico exploration of possible pharmacological potentials of bromophenol compounds by the aid of Schrodinger Maestro 9.1 software against six pharmacotherapeutic targets; Dipeptidyl peptidase (anti-diabetic), Angiotensin-1-Converting Enzyme (anti-hypertensive), Cyclin-Dependent Kinase-5 (anti-cancer), Protein kinase C (anti-cancer), Lipoxygenase-5 (anti-inflammatory), and Cycloxygenase-2 (anti-inflammatory). The docking scores, referred to as Glide Scores were reported for each ligand against specific drug targets and from this study, a conclusion was drawn for their future applications. The IFD results were impressive with low Glide Score due to interaction with the amino acid residues of the active site through the formation of strong hydrogen bonding, π-π interactions, and Van der Waals forces via hydroxyl group and oxygen-atom. The validated in silico study furthermore will definitely open innovative avenues of pharmacological research in the rational development of dual inhibitors and multi-targeted ligands. This approach for the endless search of natural products towards new biological activities will open doors for the academicians, modern scientists, and researchers and also provide better perspectives for pharmacotherapeutics.
Keywords: Bromophenol, Molecular docking, In silico, Therapeutic target, Multi-targeted, Inhibitors
Cite this Article
Tomy Muringayil Joseph, Debarshi Kar Mahapatra. Multifarious Pharmacother
apeutic Perspectives of Some Natural Bromophenol Compounds: In silico Enzyme Inhibitory Potentials. Research & Reviews: A Journal of Drug Design & Discovery. 2019; 6(2): 24–29p.
References
Mahapatra DK, Bharti SK, Asati V. Chalcone derivatives: Anti-inflammatory potential and molecular targets perspectives. Curr Top Med Chem. 2017;17(28):3146–69p.
Mahapatra DK, Bharti SK, editors. Pharmacological Perspectives of Low Molecular Weight Ligands, 1st Edn. New Jersey: Apple Academic Press; 2019.
Mahapatra DK, Bharti SK. Medicinal Chemistry with Pharmaceutical Product Development, 1st Edn. New Jersey: Apple Academic Press; 2019.
Mahapatra DK, Bharti SK. Handbook of Research on Medicinal Chemistry: Innovations and Methodologies, 1st Edn. New Jersey: Apple Academic Press; 2017.
Mahapatra DK, Bharti SK. Drug Design, 1st Edn. New Delhi, India: Tara Publications Private Limited; 2016.
Chhajed SS, Bastikar V, Bastikar AV, Mahapatra DK. Computer Aided Drug Design, 1st Edn. Pune: Everest Publishing House; 2019.
Chhajed SS, Upasani C, Wadher SJ, Mahapatra DK. Medicinal Chemistry, 1st Edn. Nashik: Career Publications Private Limited; 2017.
Joseph TM, Mahapatra DK. Bacterial DNA Gyrase (Topoisomerase) Inhibitory Potentials of Heterocyclic Natural Products: Investigations through Induced-Fit Molecular Docking Approach. Res Rev J Drug Des Discov. 2018;5(2):7-9p.
Joseph TM, Mahapatra DK. Induced-Fit Molecular Docking and Pharmacokinetic Prediction Studies of Two Phenanthrene Compound Series as Potential Cyclooxygenase-2 (COX-2) and Lipoxygenase (LOX) Inhibitors: Edema Reducing Prospects of the Emerging Candidates. Res Rev Journal Bioinformat. 2018;5(3):1-8p.
Joseph TM, Mahapatra DK. A Nascent Step towards the Discovery of New Generation Non-Steroidal Anti-inflammatory Agents (NSAIDs): Induced-Fit Molecular Docking and Pharmacokinetic Prediction Studies of Some Chromene Derivatives as Potential Cyclooxygenase-2 (COX-2) and Lipoxygenase (LOX) Inhibitors. Res Rev J Boinformat. 2018;5(2):30-36p.
Downloads
Published
Issue
Section
License
Declaration and Copyright Transfer Form
(to be completed by authors)
I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.
- I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
- I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
- I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
- I/We also agree to the authorship of the article in the following order:
Author’s name
1. ________________
2. ________________
3. ________________
4. ________________
| We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal. |